Genetically-informed Therapy for ER+ Breast Cancer Post-CDK4/6 Inhibitor — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Genetically-informed Therapy for ER+ Breast Cancer Post-CDK4/6 Inhibitor — Stella

Home/Advanced Breast Cancer/

View on ClinicalTrials.gov

Recruiting

Back to Advanced Breast Cancer trials

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(1 site)

United States

Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire

Key details

Phase

Safety & dosing

Sponsor

Dartmouth-Hitchcock Medical Center

Enrollment target

~135 participants

Started

September 2024

Primary completion

October 2030

Age range

18 Years and older

Sex

Female only

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

Last updated January 2026